Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22583253 | 0.85 | CACNA1G (0.34) | BRD4PAX8LIPEALDH1A1 | |
| SCHEMBL22583203 | 0.82 | — | — | |
| SCHEMBL29435779 | 0.77 | BRD4 (0.38) | BRD4PAX8LIPECREBBPALDH1A1 | |
| SCHEMBL29435629 | 0.77 | NOS3 (0.39) | BRD4PAX8LIPECREBBPALDH1A1 | |
| SCHEMBL22583230 | 0.75 | ALDH1A1 (0.37) | LIPEALDH1A1 | |
| SCHEMBL29435617 | 0.74 | P2RX3 (0.31) | — | |
| SCHEMBL22582915 | 0.74 | P2RX3 (0.31) | — | |
| SCHEMBL29435573 | 0.74 | ALDH1A1 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL22583395 | 0.72 | APLNR (0.36) | BRD4PAX8GABRA1GABRG2GABRB3 | |
| SCHEMBL30400464 | 0.70 | PAX8 (0.40) | BRD4PAX8CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | BRD4 2590/4885PAX8 4566/4885GABRA1 2750/4885 |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | BRD4 2590/4885PAX8 4566/4885GABRA1 2750/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | BRD4 2590/4885PAX8 4566/4885GABRA1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.